Düsseldorf – Leading global law firm Mayer Brown advised Shanghai Fosun Pharmaceutical Group (Fosun Pharma) on their acquisition of an interest (37 percent) in miacom Diagnostics GmbH in Düsseldorf as well as on the conclusion of a cooperation agreement.
Fosun Pharma, based in Shanghai, is a leading healthcare company in China. Established in 1994, it has been listed on Shanghai Stock Exchange since August 1998. Fosun Pharma develops, produces and distributes pharmacueticals, healthcare services, diagnostic products and medical devices.

Miacom diagnostics, established in 2006, specializes on medical tests for the detection of pathogens causing infections such as sepsis and pneumonia.

The Mayer Brown working on the transaction encompassed partners Carsten Flaßhoff (lead, Corporate, Düsseldorf), Dr. Marco Wilhelm (lead, Corporate, Frankfurt), Betty F.K. Tam (Corporate, Shanghai), Dr. Marius Boewe (Public Law, Düsseldorf) as well as associates Gavin W.H. Guo (Corporate, Shanghai), Konstantin von Werder (IP, Frankfurt) and Roman Wille (Corporate, Düsseldorf).